Diarrhea News and Research

Latest Diarrhea News and Research

Takeda enters co-promotion agreement with Janssen Pharma for VELCADE

Takeda Pharmaceutical Company Limited and its wholly owned subsidiary Millennium: The Takeda Oncology Company today announced that Takeda has entered into a co-promotion agreement with Janssen Pharmaceutical K.K. for VELCADE® (bortezomib) for Injection, a treatment for patients with multiple myeloma.

10 May 2010

GSK participates in FDA advisory committee's rotavirus vaccine meeting

GlaxoSmithKline today participated in a U.S. Food and Drug Administration (FDA) advisory committee meeting convened to discuss recent findings of porcine circovirus (PCV) in rotavirus vaccines. Although the committee did not issue any formal recommendations, members widely acknowledged that the benefits of vaccinating infants worldwide against rotavirus disease clearly outweigh the theoretical risks associated with the presence of porcine circovirus type 1 (PCV-1) in the vaccines.

10 May 2010

Urgent care and retail health clinics can reduce treatment costs for allergy sufferers

In this economy, allergy sufferers are looking for relief from more than sneezing, runny noses, and itchy eyes. And, according to a recent study, they can find relief for both their symptoms and their wallets, saving anywhere from $50 to $400 in out-of-pocket costs per visit if they skip the emergency room and head to urgent care and retail health clinics when they are unable to see their primary physician.

10 May 2010

Data comparing NUCYNTA to oxycodone IR for osteoarthritis pain presented at 29th APS

A post-hoc analysis of a Phase 3 safety study demonstrated that NUCYNTA® (tapentadol) tablets were associated with a lower incidence of nausea, vomiting and constipation when compared to oxycodone immediate release (IR) tablets in elderly patients with moderate to severe low-back or osteoarthritis pain.

7 May 2010

FDA assigns BYDUREON new PDUFA action date of October 22, 2010

Amylin Pharmaceuticals, Inc., Eli Lilly and Company and Alkermes, Inc. today announced that the U.S. Food and Drug Administration (FDA) has classified the BYDUREON™ (exenatide for extended-release injectable suspension) complete response as a Class 2 resubmission and assigned a new Prescription Drug User Fee Act (PDUFA) action date of October 22, 2010.

6 May 2010

New blood test could increase success of lung cancer drug erlotinib: Study

A new blood test could increase the success of a popular lung cancer drug called erlotinib by allowing doctors select which patients will react positively to the drug.

6 May 2010

Latest LLMDA technology available to detect viruses, bacteria

Law enforcement authorities seeking to detect bioterrorism attacks, doctors diagnosing diseases and regulatory agencies checking product safety may find a new ally in a Lawrence Livermore National Laboratory detection technology.

6 May 2010

Targeted antibiotics provide safe, long-lasting improvement for IBS patients, says study

A targeted antibiotic provides effective and long-lasting relief of Irritable Bowel Syndrome symptoms, according to the results of two multisite Phase III clinical trials designed by Cedars-Sinai researchers. Rifaximin is the first drug treatment for IBS that relieves symptoms while it's being administered and continues to benefit patients after they stop taking the drug.

5 May 2010

Alvine Pharmaceuticals reports data of ALV003 in gastric simulation model at DDW 2010

Alvine Pharmaceuticals, Inc., today announced the reporting of scientific data on the performance of its lead compound, ALV003, in a gastric simulation model. The data were presented at the 2010 Digestive Disease Week (DDW) meeting held in New Orleans, Louisiana.

5 May 2010

Vitamin A does not improve maternal, infant health, study finds

Giving women vitamin A supplements does not reduce maternal death rates or improve the health of infants, according to a study published Tuesday in the Lancet, the New York Times reports.

5 May 2010

Mayo Clinic researchers identify genetic variants in serotonin genes that impact IBS

Most people associate serotonin with brain neurology, but over 95 percent of the body's serotonin occurs in the gastrointestinal tract, which has a complex neuronal circuit that has been called "the second brain" of the body.

5 May 2010

Second fidaxomicin Phase 3 clinical study data in patients with CDI to be presented at DDW 2010

Optimer Pharmaceuticals, Inc. announced the presentation of new data from its second fidaxomicin Phase 3 clinical study in patients with Clostridium difficile infection. The data, presented by Stuart Johnson, M.D. during an oral session at the annual meeting of Digestive Disease Week in New Orleans, indicated that treatment with fidaxomicin significantly improved the recurrence rate and global cure rate in CDI patients requiring concomitant antibiotics, compared to vancomycin.

5 May 2010

Novel biomarker test predicts risk of disease progression in patients with Crohn's disease

Prometheus Laboratories Inc., a specialty pharmaceutical and diagnostic company, announced new findings supporting a novel, algorithm-based biomarker test that helps clinicians effectively predict the risk of developing aggressive disease in patients with Crohn's disease.

4 May 2010

Breast-feeding may help lower risk of death from Shigella infection in developing countries: Study

Teaching parents about the importance of continued breast-feeding may help to lower the risk of death from brain disease (encephalopathy) related to Shigella infection in developing countries, reports a study in the May issue of The Pediatric Infectious Disease Journal.

4 May 2010

Ansell introduces new surgical glove with AMT Antimicrobial Technology

Ansell today announced the launch of their new GAMMEX(R) Powder-Free glove with AMT Antimicrobial Technology, at the Annual Congress of the Royal Australasian College of Surgeons in Perth, Australia.

4 May 2010

Data from Phase IV study of Bystolic tablets in Hispanic patients with hypertension presented at ASH 2010

Forest Laboratories, Inc. today presented data from a Phase IV study evaluating the effects of Bystolic (nebivolol) tablets in Hispanic patients with hypertension at the 2010 annual scientific meeting of the American Society of Hypertension.

4 May 2010

WHO, UNICEF issue guide, call for more research into medicines for children

Along with the release of a WHO-UNICEF guide on medicines for children, the U.N. agencies on Friday said the guide "exposed dangerous shortfalls" in medicines designed for children and called for more research into treating children, Reuters reports. "While effective medicines exist to fight disease and treat life-threatening conditions like malnutrition, formulations suitable for children are often difficult to source," Francisco Blanco, UNICEF's chief of medicines and nutrition, said, according to the news service.

3 May 2010

FDA approves Abbott's CREON sNDA including dosing guidance for treating EPI due to CP, pancreatectomy

Abbott announced that the U.S. Food and Drug Administration (FDA) approved the supplemental New Drug Application (sNDA) for CREON® (pancrelipase) Delayed-Release Capsules that now includes dosing guidance in the prescribing information specific to patients with limited production of enzymes in the pancreas (exocrine pancreatic insufficiency) due to chronic pancreatitis (CP) or removal of the pancreas (pancreatectomy). Prior to this FDA approval, dosing guidance for medications such as CREON was based on patients with cystic fibrosis.

3 May 2010

Vita Breath may contain hazardous levels of lead, warns FDA

The U.S. Food and Drug Administration is advising consumers not to purchase nor consume Vita Breath, a dietary supplement manufactured by American Herbal Lab Inc. of Rosemead, Calif., and marketed at health fairs and on the Internet, because the product may contain hazardous levels of lead.

3 May 2010

VIMOVO delayed-release tablets receive FDA approval

AstraZeneca and POZEN Inc. today announced the U.S. Food and Drug Administration has approved VIMOVO (naproxen and esomeprazole magnesium) delayed-release tablets for the relief of signs and symptoms of osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis, and to decrease the risk of developing gastric ulcers in patients at risk of developing NSAID-associated gastric ulcers.

3 May 2010

Diarrhea News and Research

Latest Diarrhea News and Research

Takeda enters co-promotion agreement with Janssen Pharma for VELCADE

GSK participates in FDA advisory committee's rotavirus vaccine meeting

Urgent care and retail health clinics can reduce treatment costs for allergy sufferers

Data comparing NUCYNTA to oxycodone IR for osteoarthritis pain presented at 29th APS

FDA assigns BYDUREON new PDUFA action date of October 22, 2010

New blood test could increase success of lung cancer drug erlotinib: Study

Latest LLMDA technology available to detect viruses, bacteria

Targeted antibiotics provide safe, long-lasting improvement for IBS patients, says study

Alvine Pharmaceuticals reports data of ALV003 in gastric simulation model at DDW 2010

Vitamin A does not improve maternal, infant health, study finds

Mayo Clinic researchers identify genetic variants in serotonin genes that impact IBS

Second fidaxomicin Phase 3 clinical study data in patients with CDI to be presented at DDW 2010

Novel biomarker test predicts risk of disease progression in patients with Crohn's disease

Breast-feeding may help lower risk of death from Shigella infection in developing countries: Study

Ansell introduces new surgical glove with AMT Antimicrobial Technology

Data from Phase IV study of Bystolic tablets in Hispanic patients with hypertension presented at ASH 2010

WHO, UNICEF issue guide, call for more research into medicines for children

FDA approves Abbott's CREON sNDA including dosing guidance for treating EPI due to CP, pancreatectomy

Vita Breath may contain hazardous levels of lead, warns FDA

VIMOVO delayed-release tablets receive FDA approval

How microRNA is transforming science: From discovery to diagnostics

Advancing benzodiazepine detection

The Surgeon-Scientist Pioneering Regenerative Engineering

Diarrhea News and Research

Latest Diarrhea News and Research

How microRNA is transforming science: From discovery to diagnostics

Advancing benzodiazepine detection

The Surgeon-Scientist Pioneering Regenerative Engineering

Newsletters you may be interested in